Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1980 1
1986 4
1988 4
1989 7
1990 9
1991 7
1992 43
1993 78
1994 110
1995 149
1996 229
1997 274
1998 340
1999 407
2000 435
2001 456
2002 460
2003 511
2004 571
2005 614
2006 689
2007 684
2008 711
2009 698
2010 787
2011 842
2012 924
2013 927
2014 1001
2015 909
2016 858
2017 859
2018 896
2019 803
2020 607
2021 1
Text availability
Article attribute
Article type
Publication date

Search Results

15,043 results
Results by year
Filters applied: . Clear all
Page 1
Drugs behave as substrates, inhibitors and inducers of human cytochrome P450 3A4.
Zhou SF. Zhou SF. Curr Drug Metab. 2008 May;9(4):310-22. doi: 10.2174/138920008784220664. Curr Drug Metab. 2008. PMID: 18473749 Review.
Human cytochrome P450 (CYP) 3A4 is the most abundant hepatic and intestinal phase I enzyme that metabolizes approximately 50% marketed drugs. ...A number of important drugs have been identified as substrates, inducers and/or inhibitors of CYP3A4. The ability of drug …
Human cytochrome P450 (CYP) 3A4 is the most abundant hepatic and intestinal phase I enzyme that metabolizes approximately 50% markete …
Functional gene variants of CYP3A4.
Werk AN, Cascorbi I. Werk AN, et al. Clin Pharmacol Ther. 2014 Sep;96(3):340-8. doi: 10.1038/clpt.2014.129. Epub 2014 Jun 13. Clin Pharmacol Ther. 2014. PMID: 24926778 Review.
Cytochrome P450 3A4 (CYP3A4) is involved in the metabolism of more drugs in clinical use than any other foreign compound-metabolizing enzyme in humans. ...This review article highlights the functional consequences of all CYP3A4 variants recognized by the Huma
Cytochrome P450 3A4 (CYP3A4) is involved in the metabolism of more drugs in clinical use than any other foreign compound-metab
Plasma extracellular nanovesicle (exosome)-derived biomarkers for drug metabolism pathways: a novel approach to characterize variability in drug exposure.
Rowland A, Ruanglertboon W, van Dyk M, Wijayakumara D, Wood LS, Meech R, Mackenzie PI, Rodrigues AD, Marshall JC, Sorich MJ. Rowland A, et al. Br J Clin Pharmacol. 2019 Jan;85(1):216-226. doi: 10.1111/bcp.13793. Epub 2018 Nov 16. Br J Clin Pharmacol. 2019. PMID: 30340248 Free PMC article.
AIMS: Demonstrate the presence of cytochrome P450 (CYP) and UDP-glucuronosyltransferase (UGT) proteins and mRNAs in isolated human plasma exosomes and evaluate the capacity for exosome-derived biomarkers to characterize variability in CYP3A4 activity. ...R(2) values …
AIMS: Demonstrate the presence of cytochrome P450 (CYP) and UDP-glucuronosyltransferase (UGT) proteins and mRNAs in isolated human pl …
Differential Regulation of CYP3A4 and CYP3A5 and its Implication in Drug Discovery.
Lolodi O, Wang YM, Wright WC, Chen T. Lolodi O, et al. Curr Drug Metab. 2017;18(12):1095-1105. doi: 10.2174/1389200218666170531112038. Curr Drug Metab. 2017. PMID: 28558634 Free PMC article. Review.
METHODS: We performed a structured search of peer-reviewed literature on P450 (CYP) 3A, with a focus on CYP3A4 and CYP3A5. RESULTS: Recent reports indicate that components of the xenobiotic response system are upregulated in some diseases, including many cancers. Such comp …
METHODS: We performed a structured search of peer-reviewed literature on P450 (CYP) 3A, with a focus on CYP3A4 and CYP3A5. RESULTS: R …
Metabolism of tacrolimus (FK506) and recent topics in clinical pharmacokinetics.
Iwasaki K. Iwasaki K. Drug Metab Pharmacokinet. 2007 Oct;22(5):328-35. doi: 10.2133/dmpk.22.328. Drug Metab Pharmacokinet. 2007. PMID: 17965516 Free article. Review.
Tacrolimus was metabolized by the cytochrome P450 (CYP) 3A subfamily. Metabolic drug-drug interaction studies were conducted to provide information regarding the optimal usage of tacrolimus, and its metabolism was inhibited by known CYP3A inhibitors such as ketocona …
Tacrolimus was metabolized by the cytochrome P450 (CYP) 3A subfamily. Metabolic drug-drug interaction studies were conducted to provi …
Functional characterization of 27 CYP3A4 variants on macitentan metabolism in vitro.
Li YH, Lu XR, Lin QM, Huang HL, Liang XL, Cai JP, Cui J, Hu GX. Li YH, et al. J Pharm Pharmacol. 2019 Nov;71(11):1677-1683. doi: 10.1111/jphp.13153. Epub 2019 Aug 22. J Pharm Pharmacol. 2019. PMID: 31441067
OBJECTIVE: Macitentan is a new choice for pulmonary hypertension treatment which is converted to active metabolite ACT132577 by human cytochrome P450 3A4. Human cytochrome P450 3A4 often occurred gene mutations. Gene polymorphism might cause a variety of changes of …
OBJECTIVE: Macitentan is a new choice for pulmonary hypertension treatment which is converted to active metabolite ACT132577 by human cyt
[Grapefruit juice: casual detection and interaction prevention].
Cornejo Uixeda S, Luna Calatayud P, Sánchez Alcaraz A. Cornejo Uixeda S, et al. Nutr Hosp. 2019 Apr 10;36(2):496. doi: 10.20960/nh.2476. Nutr Hosp. 2019. PMID: 30864454 Free article. Spanish. No abstract available.
Guidance for Rifampin and Midazolam Dosing Protocols To Study Intestinal and Hepatic Cytochrome P450 (CYP) 3A4 Induction and De-induction.
Kapetas AJ, Sorich MJ, Rodrigues AD, Rowland A. Kapetas AJ, et al. AAPS J. 2019 Jun 19;21(5):78. doi: 10.1208/s12248-019-0341-y. AAPS J. 2019. PMID: 31218462
Cytochrome P450 3A4 (CYP3A4) catalyses the metabolism of > 30% of clinically used small molecule drugs. Induction of CYP3A4 is often associated with clinically important metabolic drug-drug interactions (DDIs). ...Maximal induction of intestinal CYP3A4
Cytochrome P450 3A4 (CYP3A4) catalyses the metabolism of > 30% of clinically used small molecule drugs. Induction of CYP
Tofacitinib Is a Mechanism-Based Inactivator of Cytochrome P450 3A4.
Guo X, Li W, Li Q, Chen Y, Zhao G, Peng Y, Zheng J. Guo X, et al. Chem Res Toxicol. 2019 Sep 16;32(9):1791-1800. doi: 10.1021/acs.chemrestox.9b00141. Epub 2019 Aug 26. Chem Res Toxicol. 2019. PMID: 31414593
Incubation (40 min, 37 °C) of recombinant CYP3A4 with TFT at 200 μM resulted in >70% loss of CYP3A4 activity. Estimated k(inact) and K(I) were 0.037 min(-1) and 93.2 μM, respectively. GSH and superoxide dismutase/catalase revealed minor or little protection again …
Incubation (40 min, 37 °C) of recombinant CYP3A4 with TFT at 200 μM resulted in >70% loss of CYP3A4 activity. Estimated k(i …
Evaluation of cytochrome P450 3A4‑mediated drug‑drug interaction potential between P2Y12 inhibitors and statins.
Zhang B, Zhan G, Fang Q, Wang F, Li Y, Zhang Y, Zhao L, Zhang G, Li B. Zhang B, et al. Mol Med Rep. 2019 Nov;20(5):4713-4722. doi: 10.3892/mmr.2019.10692. Epub 2019 Sep 19. Mol Med Rep. 2019. PMID: 31545497
The activity of cytochrome P450 family 3 subfamily A member 4 (CYP3A4) was detected, and its protein and mRNA expression levels were measured in a rat model and liver microsomes to evaluate the effect of the drug combinations on CYP3A4. ...The in vitro experi …
The activity of cytochrome P450 family 3 subfamily A member 4 (CYP3A4) was detected, and its protein and mRNA expression level …
15,043 results
Jump to page
Feedback